November 4, 2019 at 11:50AM in the Montréal 2&3 Conference room, at the Till&McCulloch Meeting in Montréal.

This workshop will feature the critical quality attributes required for iPSC-based research projects to meet clinical grade specifications for cGMP manufacturing and lot release. Emphasis will be placed on process validation and standard operating procedure development needed to standardize quality control (QC) of iPSC production. These modifications can improve laboratory efficiency, increase experimental reproducibility, and optimize manufacturing scaleability.

Speakers will describe their ideal QC workflow based on real case studies. International consensus-built QC guidelines will be compared with those developed here in Canada. Canadian and international perspectives from the Montreal Neurological Institute and the Global Alliance for iPSC Therapies will be presented and discussed.

Speakers:
Dr. Thomas Durcan, Associate Director, Early Drug Discovery Unit (EDDU), Montreal Neurological Institute-Hospital (The Neuro), Assistant Professor, Department of Neurology and Neurosurgery, McGill University

Dr. Stephen Sullivan, International Liaison Officer, Global Alliance for iPSC Therapies (GAiT)